Micro/nanomotor development towards enhanced cancer therapy.

J Mater Chem B

State Key Laboratory of New Pharmaceutical Preparations and Excipients, Key Laboratory of Medicinal Chemistry and Molecular Diagnosis of the Ministry of Education, Chemical Biology Key Laboratory of Hebei Province & College of Chemistry and Materials Science, Hebei University, Baoding, 071002, P. R.

Published: August 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Cancer remains a leading global life-threatening disease, with traditional cancer therapies hindered by inefficient drug delivery and the complex tumor microenvironment. Micro/nanomotors-nanomaterials capable of converting chemical, physical, or biological energy into autonomous mechanical motion-emerge as a transformative tool for precision oncology. By overcoming the limitations of passive drug carriers, these motors enable active penetration of tumor barriers, targeted cargo delivery, and spatiotemporally controlled therapy, offering unprecedented opportunities to enhance treatment efficacy and reduce systemic toxicity. This review synthesizes the latest advancements in micro/nanomotors for cancer therapy, taking their diverse driving mechanisms as the central axis to explore their therapeutic potential. The article systematically categorizes these motors into chemical-driven (, bubbles, self-electrophoresis, and enzymes), physical-driven (, magnetic, ultrasonic, and light), multifield-coupled, and bio-hybrid systems. For each category, we elaborate on design principles, energy-conversion mechanisms, cancer-specific applications (, targeted delivery, combinatorial therapy, and immune activation), and technical advantages, illustrating how different driving modalities address unique challenges in tumor microenvironments. Future progress requires interdisciplinary efforts to bridge experimental design with practical applications, aiming to transform these micro/nanomotors into effective tools for precise cancer therapy.

Download full-text PDF

Source
http://dx.doi.org/10.1039/d5tb01094bDOI Listing

Publication Analysis

Top Keywords

cancer therapy
12
cancer
5
therapy
5
micro/nanomotor development
4
development enhanced
4
enhanced cancer
4
therapy cancer
4
cancer remains
4
remains leading
4
leading global
4

Similar Publications

Dual-Mode Hybrid Discharge Plasma-Activated Injectable Hydrosol for Enhanced Immunotherapeutic Cancer Therapy.

Adv Healthc Mater

September 2025

Department of Physics, Department of Materials Science and Engineering, and Department of Biomedical Engineering, City University of Hong Kong, Tat Chee Avenue, Kowloon, Hong Kong, China.

Although cold atmospheric plasma is a promising therapeutic technique for tumor immunotherapy via reactive oxygen and nitrogen species (RONS), the challenges associated with the generation and delivery of these RONS hamper clinical adoption. Herein, a dual-mode hybrid discharge plasma-activated sodium alginate hydrosols (PAH) is proposed to enhance the antitumor immune response. Gaseous highly reactive RONS are generated by dual-mode hybrid plasma produced by mixed O and NO modes, which are converted into aqueous RONS in PAH via gas-liquid reactions between plasma and hydrosols.

View Article and Find Full Text PDF

Background: Inflammation impacts the prognosis of numerous types of tumors. Inflammatory indicators such as the neutrophil-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, and neutrophil-to-eosinophil ratio (NER) have emerged as potential prognostic markers and are closely correlated with the outcomes of cancer patients. However, the connection between NER and cancer prognosis remains incompletely understood.

View Article and Find Full Text PDF

Background: Lenvatinib plus pembrolizumab (LP) therapy has emerged as an effective treatment for patients with advanced or recurrent endometrial cancer. However, limited data are available regarding its outcomes in real-world settings. This study aimed to identify prognostic factors associated with the efficacy of LP therapy.

View Article and Find Full Text PDF

Harnessing biomarkers to guide immunotherapy in esophageal cancer: toward precision oncology.

Clin Transl Oncol

September 2025

Department of Basic Science, College of Medicine, Princess Nourah bint Abdulrahman, University, P.O.Box 84428, 11671, Riyadh, Saudi Arabia.

Esophageal cancer (EC) is one of the most serious health issues around the world, ranking seventh among the most lethal types of cancer and eleventh among the most common types of cancer worldwide. Traditional therapies-such as surgery, chemotherapy, and radiation therapy-often yield limited success, especially in the advanced stages of EC, prompting the pursuit of novel and more effective treatment strategies. Immunotherapy has emerged as a promising option; nonetheless, its clinical success is hindered by variable patient responses.

View Article and Find Full Text PDF

A major cause of cancer death, colorectal cancer is becoming more common in younger people. The comparative effectiveness of robotic versus laparoscopic total mesorectal excision (TME) as surgical interventions for mid-low rectal cancer following neoadjuvant chemoradiotherapy (nCRT) remains uncertain. To systematically evaluate oncological, perioperative, and survival outcomes of robotic versus laparoscopic surgery for mid-low rectal cancer following nCRT.

View Article and Find Full Text PDF